WATHealthcare · Diagnostics & Research

WAT Stock Forecast: Waters Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026

$412

−0.32% on the day

The 24 Wall Street analysts covering Waters Corp. hold a median 12-month price target of $440 — +6.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 15 Aug 2026 — in the lower half.

Market cap

$40.5B

Ticker Nerd rank

49 / 100

Median analyst target

$440

Analysts covering

Total return, dividends reinvested

+1.3%

+9.5%

YTD

+8.5%

+40.4%

From 52W high

−1.0%

From 52W low

+45.5%

$283

$416

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

WAT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Waters Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026

49 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility

Revisions

Value

Momentum

Quality

Growth

Accruals

Issuance

Size

Volatility (88): The share price has been relatively steady.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

WAT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on WAT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says24 analysts

16 Buy8 Hold0 Sell

Low $349Median $440High $475

The green dot is the last close — the median target sits +6.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

Date	Firm	Action	Rating	Target
10 Aug 2026	Citigroup	Maintains	Buy	$425 → $470
5 Aug 2026	Barclays	Maintains	Overweight	$425 → $460
5 Aug 2026	Evercore ISI Group	Maintains	Outperform	$410 → $420
5 Aug 2026	RBC Capital	Maintains	Outperform	$435 → $475
5 Aug 2026	TD Cowen	Upgrade	Buy	$408 → $475
5 Aug 2026	Wells Fargo	Maintains	Equal-Weight	$370 → $400
14 July 2026	Goldman Sachs	Maintains	Buy	$380 → $425
14 July 2026	Goldman Sachs	Maintains	Buy	—
9 July 2026	Morgan Stanley	Maintains	Equal-Weight	—
9 July 2026	Morgan Stanley	Maintains	Equal-Weight	$350 → $390
9 July 2026	RBC Capital	Initiates	Outperform	$435
9 July 2026	RBC Capital	Initiates	Outperform	—
8 July 2026	Guggenheim	Reiterates	Buy	$440
8 July 2026	Guggenheim	Reiterates	Buy	—
6 July 2026	Evercore ISI Group	Maintains	Outperform	$380 → $410
6 July 2026	Evercore ISI Group	Maintains	Outperform	—
26 June 2026	Bernstein	Reinstates	Outperform	$435
11 June 2026	Piper Sandler	Initiates	Neutral	—
3 June 2026	HSBC	Maintains	Buy	—
2 June 2026	B of A Securities	Maintains	Neutral	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. WAT appears on the weeks it earns a place.

Estimates

WAT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

EPS revision, 90 days

+0.6%

Analysts raising

Analysts cutting

Fundamentals

Waters Corp. (WAT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 104.1×
Price / sales: 8.7×
Price / book: 2.6×
EV / EBITDA: 31.3×

Growth & margins

Revenue growth (YoY): 113.4%
Earnings growth (YoY): 91.5%
Gross margin: 46.4%
Operating margin: 9.4%
Net margin: 3.6%

Returns & dividend

Return on equity: 1.9%
Return on assets: 3.6%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

WAT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research

Company	Market cap	TKN rank
WATWaters Corp.	$40.5B	49
IQVIQVIA Holdings, Inc.	$39.0B	92
AAgilent Technologies, Inc.	$42.1B	88
NTRANatera, Inc.	$42.8B	79
IDXXIDEXX Laboratories, Inc.	$44.0B	93
ILMNIllumina, Inc.	$29.3B	96
MTDMettler-Toledo International, Inc.	$29.0B	92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Waters Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest WAT news & analysis

Waters Q2 Earnings Call Highlights

MarketBeat · 9 Aug 2026positive

Waters reported second-quarter 2026 revenue of $1.645 billion, driven by 9% organic constant-currency growth and a 4% increase from its acquired Biosciences and Diagnostic Solutions businesses. The company raised its full-year guidance for organic revenue, acquired-business revenue and adjusted earnings per share after results exceeded prior expectations.

Why it matters — WAT watchers would care because the raised full-year outlook indicates the company's growth exceeded its initial guidance for the quarter.

Waters Q2 Earnings Beat Estimates, 2026 Revenue Growth View Raised

Zacks Investment Research · 5 Aug 2026positive

Waters beat Q2 earnings estimates and raised its 2026 outlook, with growth reported across its organic and acquired businesses.

Why it matters — The outperformance and updated guidance give Waters watchers a more favorable read on the company's recent results and its forward expectations.

Oakmark Global Strategy Q2 2026 Portfolio Activity

Seeking Alpha · 5 Aug 2026neutral

Oakmark Global Strategy's Q2 2026 portfolio commentary discusses several holdings, noting that Accor trades at a discount to asset-light peers despite strong delivery, that Amrize is a fundamentally strong business under the radar of U.S. investors, and that Compass Group's scale and operating model support consistent growth and margin progression.

Why it matters — The piece does not mention Waters Corp., so it offers no direct insight for WAT watchers other than context on the fund's separate holdings.

Waters Corporation (WAT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

Seeking Alpha published the transcript of Waters Corporation's (WAT) second-quarter 2026 earnings call. The item is limited to the headline and source, with no additional content in the provided text.

Why it matters — An earnings call transcript gives WAT watchers direct access to management's discussion of the company's quarterly results.

Waters (WAT) Q2 Earnings and Revenues Beat Estimates

Zacks Investment Research · 4 Aug 2026positive

Waters reported Q2 earnings of $3.05 per share, beating the Zacks Consensus Estimate of $3.01 per share and up from $2.95 per share a year ago. This marks an earnings beat for the quarter.

Why it matters — A WAT watcher would track this because the company exceeded earnings expectations and improved on its year-ago result.

FAQ

Frequently asked questions about WAT stock

What is the WAT stock price forecast for 2026-2027?

The 24 Wall Street analysts covering Waters Corp. have a median 12-month price target of $440, with estimates ranging from $349 to $475. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is WAT stock a buy right now?

Of the 24 analysts covering Waters Corp., 16 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Waters Corp. 49 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank WAT?

As at 15 Aug 2026, Waters Corp. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (88 of 100).

Will WAT stock go up?

No one can know that. What the data says: the median 12-month target from 24 analysts implies +6.8% from the last close, and Ticker Nerd's factor model ranks Waters Corp. 49 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the WAT stock forecast for 2030?

No analyst covering Waters Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for WAT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $349 to $475 over the next 12 months.

How has WAT stock performed over the past year?

Waters Corp. returned +40.4% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Waters Corp. do?

What is the latest news on WAT?

The most recent item we track (MarketBeat, 9 Aug 2026): "Waters Q2 Earnings Call Highlights". Waters reported second-quarter 2026 revenue of $1.645 billion, driven by 9% organic constant-currency growth and a 4% increase from its acquired Biosciences and Diagnostic Solutions businesses. The company raised its full-year guidance for organic revenue, acquired-business revenue and adjusted earnings per share after results exceeded prior expectations.

Company

About Waters Corp.

Waters Corporation is a scientific instrumentation company that provides analytical workflow solutions to customers in the life sciences, industrial, and academic sectors. The company specializes in liquid chromatography systems, mass spectrometry platforms, and related precision chemistry consumables that support complex chemical and biochemical analysis. Through its Waters segment, it delivers integrated instruments, software, and services used in drug development, quality control, food and environmental testing, and advanced materials research. Its TA Instruments segment focuses on thermal analysis and rheology equipment that measure material properties such as stability, viscosity, and mechanical performance for industrial and research applications. Waters Corporation serves biopharmaceutical companies, industrial manufacturers, and government and academic laboratories globally, with a particularly strong presence in diagnostics and research-related workflows. Founded in 1958 and headquartered in Milford, Massachusetts, Waters Corporation plays a significant role in enabling precise measurement, regulatory compliance support, and data-driven decision-making across regulated and research-intensive markets.

CEO Dr. Udit Batra Ph.D. · 16,000 employees · United States · https://www.waters.com